InsiderTrades.com logo
Kathleen Goin net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Kathleen Goin Biography and Net Worth

COO of Palvella Therapeutics

With a positive and relentless spirit, Ms. Goin builds and coaches high-performing and successful clinical development teams.

Since 1998, Ms. Goin served many patient populations by developing drugs and devices to treat different cancers, heart disease/abnormalities, and pain conditions. As Vice President, Clinical Operations at Trevena, Inc., she shaped trial execution strategies across all programs by promoting meaningful and streamlined interactions between sites and sponsor representatives and employing modern processes for lean yet highly effective trial execution. These approaches led to helping the company start and finish three Phase III studies in just under two years. In 2017, she joined colleagues to start Clinical Works, a progressive specialty consulting firm focused on helping emerging and small biotech/pharmaceutical companies start their clinical programs and execute trials. Ms. Goin holds a Master of Science in Occupational Therapy from College Misericordia.

What is Kathleen Goin's net worth?

The estimated net worth of Kathleen Goin is at least $297.60 thousand as of September 16th, 2026. Goin owns 2,154 shares of Palvella Therapeutics stock worth more than $297,597 as of September 26th. This net worth evaluation does not reflect any other assets that Goin may own. Learn More about Kathleen Goin's net worth.

How do I contact Kathleen Goin?

The corporate mailing address for Goin and other Palvella Therapeutics executives is 353 W. Lancaster Avenue, Suite 200, Wayne, PA, 19087. Palvella Therapeutics can also be reached via phone at (484) 253-1461 and via email at [email protected]. Learn More on Kathleen Goin's contact information.

Has Kathleen Goin been buying or selling shares of Palvella Therapeutics?

In the last ninety days, Kathleen Goin has sold $1,309,743.90 in shares of Palvella Therapeutics stock. Most recently, Kathleen Goin sold 4,302 shares of the business's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $152.24, for a transaction totalling $654,936.48. Following the completion of the sale, the chief operating officer now directly owns 2,154 shares of the company's stock, valued at $327,924.96. Learn More on Kathleen Goin's trading history.

Who are Palvella Therapeutics' active insiders?

Palvella Therapeutics' insider roster includes Kathleen Goin (COO), Elaine Heron (Director), George Jenkins (Director), and Christopher Kiritsy (Director). Learn More on Palvella Therapeutics' active insiders.

Are insiders buying or selling shares of Palvella Therapeutics?

In the last twelve months, Palvella Therapeutics insiders bought shares 2 times. They purchased a total of 6,400 shares worth more than $800,000.00. In the last twelve months, insiders at the sold shares 11 times. They sold a total of 57,927 shares worth more than $7,716,071.58. The most recent insider tranaction occured on September, 16th when COO Kathleen Goin sold 4,302 shares worth more than $654,936.48. Insiders at Palvella Therapeutics own 17.2% of the company. Learn More about insider trades at Palvella Therapeutics.

Information on this page was last updated on 9/16/2026.

Kathleen Goin Insider Trading History at Palvella Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/16/2026Sell4,302$152.24$654,936.482,154View SEC Filing Icon  
8/19/2026Sell4,302$152.21$654,807.422,154View SEC Filing Icon  
6/17/2026Sell4,302$110.73$476,360.462,154View SEC Filing Icon  
3/18/2026Sell4,302$117.99$507,592.98View SEC Filing Icon  
1/21/2026Sell4,302$97.63$420,004.26View SEC Filing Icon  
12/17/2025Sell4,302$96.47$415,013.94View SEC Filing Icon  
11/19/2025Sell4,302$86.23$370,961.46View SEC Filing Icon  
See Full Table

Kathleen Goin Buying and Selling Activity at Palvella Therapeutics

This chart shows Kathleen Goin's buying and selling at Palvella Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Palvella Therapeutics Company Overview

Palvella Therapeutics logo
Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.
Read More

Today's Range

Now: $138.16
Low: $137.86
High: $147.44

50 Day Range

MA: $149.29
Low: $124.15
High: $158.13

2 Week Range

Now: $138.16
Low: $58.16
High: $161.38

Volume

193,330 shs

Average Volume

202,483 shs

Market Capitalization

$1.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A